NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
AUTHORS
Gradishar
WJ ,
Moran
MS ,
Abraham
J ,
Abramson
V ,
Aft
R ,
Agnese
D ,
Allison
KH ,
Anderson
B ,
Burstein
HJ ,
Chew
H ,
Dang
C ,
Elias
AD ,
Giordano
SH ,
Goetz
MP ,
Goldstein
LJ ,
Hurvitz
SA ,
Jankowitz
RC ,
Javid
SH ,
Krishnamurthy
J ,
Leitch
AM ,
Lyons
J ,
Mortimer
J ,
Patel
SA ,
Pierce
LJ ,
Rosenberger
LH ,
Rugo
HS ,
Schneider
B ,
Smith
ML ,
Soliman
H ,
Stringer-Reasor
EM ,
Telli
ML ,
Wei
M ,
Wisinski
KB ,
Young
JS ,
Yeung
K ,
Dwyer
MA ,
Kumar
R ,
. Journal of the National Comprehensive Cancer Network : JNCCN. ; 21(6). 594-608
- PMID: 37308117 [PubMed].
ABSTRACT
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly. The therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number of treatment options, if one option fails, there is usually another line of therapy available, providing meaningful improvements in survival. This NCCN Guidelines Insights report focuses on recent updates specific to systemic therapy recommendations for patients with stage IV (M1) disease.
Tags: 2023 Alumni Publications